CTI BioPharma Corp. (CTIC) Social Stream
CTI BIOPHARMA CORP (CTIC) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering CTIC.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-14 | 2 | $7 | $5.5 | $6.233 | $9.09 | -31.43% |
| 2021-11-30 | 3 | $7 | $5.5 | $6.233 | $9.09 | -31.43% |
| 2021-12-01 | 4 | $7 | $5 | $5.925 | $9.09 | -34.82% |
| 2022-01-03 | 4 | $7.2 | $5 | $6.175 | $9.09 | -32.07% |
| 2022-03-01 | 4 | $12 | $5 | $7.4 | $9.09 | -18.59% |
| 2022-03-31 | 4 | $12 | $5 | $7.35 | $9.09 | -19.14% |
| 2022-04-14 | 4 | $12 | $5 | $7.475 | $9.09 | -17.77% |
| 2022-05-13 | 4 | $12 | $5 | $7.55 | $9.09 | -16.94% |
| 2022-06-10 | 4 | $12 | $5 | $7.625 | $9.09 | -16.12% |
| 2022-07-21 | 5 | $12 | $5 | $8.3 | $9.09 | -8.69% |
| 2022-08-09 | 6 | $12 | $5 | $8.78 | $9.09 | -3.41% |
| 2022-08-10 | 6 | $12 | $7.9 | $9.58 | $9.09 | 5.39% |
| 2022-08-18 | 5 | $12 | $7.9 | $9.58 | $9.09 | 5.39% |
| 2022-09-01 | 6 | $13 | $7.9 | $10.15 | $9.09 | 11.66% |
| 2022-09-29 | 6 | $13 | $9 | $10.333 | $9.09 | 13.67% |
| 2022-10-11 | 6 | $13 | $8.7 | $10.283 | $9.09 | 13.12% |
| 2022-10-17 | 6 | $13 | $8.7 | $10.671 | $9.09 | 17.39% |
| 2022-12-12 | 7 | $13 | $8.7 | $10.671 | $9.09 | 17.39% |
| 2023-03-06 | 7 | $15 | $8.7 | $11.1 | $9.09 | 22.11% |
| 2023-03-07 | 7 | $15 | $8.1 | $11.014 | $9.09 | 21.17% |
| 2023-04-25 | 7 | $15 | $8 | $10.728 | $9.09 | 18.02% |
| 2023-05-15 | 8 | $15 | $8.1 | $10.885 | $9.09 | 19.75% |
| 2023-05-16 | 8 | $15 | $9 | $10.471 | $9.09 | 15.19% |
The Trend in the Analyst Price Target
CTIC's average price target has moved up $4.55 over the prior 18 months.
Over the past 43 weeks, CTIC's average upside potential has been 91%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-10-17 | 6 | 13 | 8.7 | 10.671 | 4.89 | 118.22% |
| 2022-10-21 | 7 | 13 | 8.7 | 10.671 | 4.45 | 139.8% |
| 2023-02-07 | 7 | 15 | 8.7 | 11.100 | 5.56 | 99.64% |
| 2023-02-27 | 7 | 15 | 8.7 | 11.100 | 5.47 | 102.93% |
| 2023-05-15 | 8 | 15 | 8.1 | 10.885 | 8.93 | 21.89% |
CTIC Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 2.5 | 2 | 0 | 6 | 0 | 0 | 8 |
The Trend in the Broker Recommendations
CTIC's average broker recommendation rating worsened by 0.98 over the prior 151 days.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for CTIC as an investment opportunity.
- To contextualize these metrics, consider that out of all US stocks, CTI BIOPHARMA CORP's average analyst price target is higher than 222.9% of them.
- In the context of stocks in the small market cap category, CTI BIOPHARMA CORP's upside potential (average analyst target price relative to current price) is higher than 220.59% of them.
- CTIC has a higher number of analysts covering the stock than 1421.71% of stocks in the small market cap category.
- In terms of how CTI BIOPHARMA CORP fares relative to Pharmaceutical Products stocks, note that its variance in analysts' estimates is lower than -834.59% of that group.
In the Pharmaceutical Products industry, GERN, VERU, and IMGN are the three stocks most similar to CTI BIOPHARMA CORP regarding the price target and analyst recommendation information presented here.
View All Top Stocks by Price Target
Make investment decisions regarding CTIC using the data that counts. Try POWR Ratings for free.